SCHEMBL326688

SCHEMBL326688

O=C(O)C(CCc1ccc(N2C(=O)C=CC2=O)cc1)N1C(=O)CCC1=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 2/20 0.49
ALDH1A1 P00352 2/20 0.49
MGLL Q99685 10/20 0.47
FAAH O00519 5/20 0.44
DDAH1 O94760 1/20 0.42
HSP90AA1 P07900 3/20 0.38
NPSR1 Q6W5P4 2/20 0.38
TDP1 Q9NUW8 2/20 0.38
MAPK1 P28482 1/20 0.38
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA9 Q16790 1/20 0.38
HPGD P15428 2/20 0.36
HTT P42858 1/20 0.36
CACNA1B Q00975 1/20 0.36
APBA1 Q02410 1/20 0.36
CHRM1 P11229 1/20 0.36
NSD2 O96028 1/20 0.36
G6PD P11413 1/20 0.36
KEAP1 Q14145 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26623027 0.86 ALDH1A1 (0.67) PKMALDH1A1MGLLFAAHDDAH1
SCHEMBL8198697 0.86 ALDH1A1 (0.52) PKMALDH1A1MGLLFAAHHSP90AA1
SCHEMBL28882413 0.81 HSP90AA1 (0.43) PKMALDH1A1MGLLFAAHDDAH1
SCHEMBL23327953 0.81 ALDH1A1 (0.54) PKMALDH1A1MAPK1HPGD
SCHEMBL6045666 0.80 MGLL (0.38) PKMALDH1A1MGLLFAAHDDAH1
SCHEMBL2169006 0.80 ALDH1A1 (0.50) PKMALDH1A1MGLLFAAHHSP90AA1
SCHEMBL1824376 0.74 DNMT1 (0.48) PKMALDH1A1MGLLFAAHNPSR1
SCHEMBL4429188 0.73 ALDH1A1 (0.50) PKMALDH1A1MGLLFAAHHSP90AA1
SCHEMBL19309442 0.73 MGLL (0.46) PKMALDH1A1MGLLFAAHDDAH1
SCHEMBL8510655 0.71 MGLL (0.49) PKMALDH1A1MGLLFAAHDDAH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1592 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3765188-B1 SURFACE FUNCTIONALISED MATERIALS FOR SAMPLING BIOLOGICAL MOLECULES JONES PAUL ANTONIO (GB) 2025-04-16 EP claimed
WO-2025054602-A1 PROTEIN FOR THE SEROLOGICAL DETECTION OF STREPTOCOCCUS EQUI SUBSPECIES EQUI EXPOSURE OR INFECTION THE TEXAS A&M UNIVERSITY SYSTEM (US) 2025-03-13 WO claimed
US-11712423-B2 Methods and compositions for modifying mucous membranes ABBOTT NICHOLAS L (US) 2023-08-01 US claimed
US-10155046-B2 Activated sialic acid derivatives for protein derivatisation and conjugation LIPOXEN TECHNOLOGIES LIMITED (GB) 2018-12-18 US claimed
EP-2686019-B1 CONJUGATED MOLECULES COMPRISING A PEPTIDE DERIVED FROM THE CD4 RECEPTOR COUPLED TO A POLYANIONIC POLYPEPTIDE FOR THE TREATMENT OF AIDS PASTEUR INSTITUT (FR) 2017-03-01 EP claimed
EP-1853634-B1 ACTIVATED SIALIC ACID DERIVATIVES FOR PROTEIN DERIVATISATION AND CONJUGATION LIPOXEN TECHNOLOGIES LTD (GB) 2016-08-10 EP claimed
EP-1776389-B1 SIALIC ACID DERIVATIVES LIPOXEN TECHNOLOGIES LTD (GB) 2016-06-29 EP claimed
US-20160120993-A1 Activated Sialic Acid Derivatives For Protein Derivatisation And Conjugation LIPOXEN TECHNOLOGIES LIMITED (GB) 2016-05-05 US claimed
US-9216227-B2 Activated sialic acid derivatives for protein derivatisation and conjugation LIPOXEN TECHNOLOGIES LIMITED (GB) 2015-12-22 US claimed
EP-2478049-B1 A POLYMER SUPPORT UNIV CAPE TOWN (ZA) 2015-02-25 EP claimed
WO-1999040214-A2 NUCLEIC ACID DELIVERY VEHICLES GENZYME CORPORATION (US) 1999-08-12 WO claimed
EP-0457250-B1 Novel bifunctional linking compounds, conjugates and methods for their production BRISTOL MYERS SQUIBB CO (US) 1999-07-14 EP claimed
EP-0633029-B1 Further improvements relating to drug delivery systems CANCER RES CAMPAIGN TECH (GB) 1997-11-26 EP claimed
EP-0396116-B1 Covalent attachment of specific binding members to a solid phase ABBOTT LAB (US) 1997-02-05 EP claimed
EP-0366770-B1 LIPOSOMES COUPLED TO HORMONES VESTAR INC (US) 1994-02-09 EP claimed
EP-0366770-A1 LIPOSOMES COUPLED TO HORMONES. SANDOZ AG (CH) 1990-05-09 EP claimed
WO-1989011270-A1 LIPOSOMES COUPLED TO HORMONES SANDOZ AG (CH) 1989-11-30 WO claimed
US-4657853-A Immunoassays utilizing covalent conjugates of polymerized enzyme and antibody E. I. DU PONT DE NEMOURS AND COMPANY (US) 1987-04-14 US claimed
EP-0184710-A2 Magnetic microspheres BAYER AG (DE) 1986-06-18 EP claimed
EP-0175560-A2 Immunoassays utilizing covalent conjugates of polymerized enzyme and antibody E.I. DU PONT DE NEMOURS AND COMPANY (US) 1986-03-26 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10155046-B2 Activated sialic acid derivatives for protein derivatisation and conjugation NANS, SPAST, NEU1 PKM 2149/4885ALDH1A1 922/4885MGLL 4237/4885
US-20160120993-A1 Activated Sialic Acid Derivatives For Protein Derivatisation And Conjugation NANS, SPAST, NEU1 PKM 2149/4885ALDH1A1 922/4885MGLL 4237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.